Eisai Licenses U.S. Rights To Fragmin From Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement to license the dalteparin sodium anti-coagulant is aimed at strengthening Eisai’s position in the U.S. critical care market.